NutriStack
Alpha-Lipoic Acid and Insulin Glargine, a caution.
Alpha-lipoic acid (ALA) enhances insulin sensitivity and glucose uptake by activating the PI3K/Akt pathway and upregulating GLUT4 transporters. When combined with insulin glargine, the improved insulin sensitivity can amplify insulin's glucose-lowering effect, increasing hypoglycemia risk. Additionally, rare cases of insulin autoimmune syndrome (IAS) have been reported with ALA, where the supplement can modify insulin structure through disulfide bond cleavage.
One pair, every claim cited. The two substances, the type, the mechanism, the recommendation, and the primary literature.
Same shape as the other 1,729 pairs in the public database.
From the interaction database
What the row says.
Every entry follows the same shape: what is happening, the mechanism, the recommendation, and the primary literature.
At a glance
- Substances
- Alpha-Lipoic Acid and Insulin Glargine
- Pair type
- Caution
- Evidence (highest tier)
- Moderate
- Source citations
- 3 sources
- Stack Score effect
- −5 to your Stack Score (per scored caution row).
- Scope
- Supplement × Prescription
- Last verified
- May 30, 2026
Caution · Moderate evidence
Caution
What is happening. Alpha-lipoic acid (ALA) enhances insulin sensitivity and glucose uptake by activating the PI3K/Akt pathway and upregulating GLUT4 transporters. When combined with insulin glargine, the improved insulin sensitivity can amplify insulin's glucose-lowering effect, increasing hypoglycemia risk. Additionally, rare cases of insulin autoimmune syndrome (IAS) have been reported with ALA, where the supplement can modify insulin structure through disulfide bond cleavage.
Mechanism. ALA activates PI3K/Akt signaling, stimulating GLUT4 translocation to the cell membrane and enhancing glucose uptake independently of insulin. It also improves mitochondrial function and reduces oxidative stress in beta cells. Combined with exogenous insulin glargine, the enhanced peripheral glucose disposal increases hypoglycemia risk. ALA may also cleave insulin disulfide bonds, triggering autoantibody formation (IAS).
Recommendation. If adding ALA to insulin therapy, start at a low dose (300 mg/day) and increase blood glucose monitoring frequency. Your prescriber may need to reduce insulin dose. Be vigilant for hypoglycemia, especially during the first 2 weeks. Report any unusual symptoms including persistent hypoglycemia despite dose adjustments.
Sources (3)
- Jacob S et al. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Arzneimittelforschung. 1995;45(8):872-874. PMID 7575750
- Hsieh RY, Huang IC, Chen C, Sung JY. Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review. Nutrients. 2023. PMID 37630823
- An P, Wan S, Luo Y, Luo J et al.. Micronutrient Supplementation to Reduce Cardiovascular Risk. Journal of the American College of Cardiology. 2022. PMID 36480969
Stack Score
How this pair moves the number.
Effect on the composite score
If both Alpha-Lipoic Acid and Insulin Glargine are in the same stack, this pair applies −5 to your Stack Score (per scored caution row).
The full algorithm, the clamping rules, and four worked stacks are documented at /methodology/stack-score.
Check your full routine
One pair was the worked example. NutriStack runs every pair in your stack at once.
Drop in your supplements and prescriptions and the public database surfaces every interaction, synergy, timing rule, and contraindication, every one linked to its primary source.